| |
All Patients n (%)
|
Groups
|
|---|
| | | | |
A, n = 84 (%)
| |
B, n = 114 (%)
| | |
|---|
| |
Dead (GOS = 1)
|
Survival GOS > 1)
|
P
|
Dead (GOS = 1)
|
Survival GOS > 1)
|
Total
|
Dead (GOS = 1)
|
Survival (GOS > 1)
|
Total
|
P
|
|---|
|
Total
|
64 (32.3)
|
134 (67.7)
| |
23 (27.4)
|
61 (72.6)
|
84
|
41 (36.0)
|
73 (64.0)
|
114
|
0.203
|
|
Age
| | | | | | | | | |
0.203
|
| ≦60 |
42 (32.3)
|
88 (67.7)
|
0.995
|
9 (20.0)
|
36 (80.0)
|
45
|
33 (38.8)
|
52 (61.2)
|
85
|
0.030
|
|
> 60
|
22 (32.4)
|
46 (67.6)
|
14 (35.9)
|
25 (64.1)
|
39
|
8 (27.6)
|
21 (72.4)
|
29
|
0.472
|
|
Gender
| | | | | | | | | |
0.203
|
|
Female
|
14 (25.9)
|
40 (74.1)
|
0.240
|
4 (18.2)
|
18 (81.8)
|
22
|
10 (31.3)
|
22 (68.8)
|
32
|
0.286
|
|
Male
|
50 (34.7)
|
94 (65.3)
|
19 (30.6)
|
43 (69.4)
|
62
|
31 (37.8)
|
51 (62.2)
|
82
|
0.373
|
|
Diabetes
| | | | | | | | | |
0.203
|
|
No
|
34 (26.8)
|
93 (73.2)
|
0.026
|
12 (20.0)
|
48 (80.0)
|
60
|
22 (32.8)
|
45 (67.2)
|
67
|
0.104
|
|
Yes
|
30 (42.3)
|
41 (57.7)
|
11 (45.8)
|
13 (54.2)
|
24
|
19 (40.4)
|
28 (59.6)
|
47
|
0.665
|
|
GCS
| | |
<0.001
| | | | | | |
0221
|
|
15-13 grade 1
|
2 (6.7)
|
28 (93.3)
| |
0 (0.0)
|
17 (100.0)
|
17
|
2 (15.4)
|
11 (84.6)
|
13
|
0.179
|
|
12-7 grade 2
|
21 (23.9)
|
67 (76.1)
|
0.059a
|
7 (18.9)
|
30 (81.1)
|
37
|
14 (27.5)
|
37 (72.5)
|
51
|
0.357
|
|
6-3 grade 3
|
41 (51.3)
|
39 (48.8)
|
<0.001b
|
16 (53.3)
|
14 (46.7)
|
30
|
25 (50.0)
|
25 (50.0)
|
50
|
0.477
|
|
NIHSS
| | |
0.001
| | | | | | |
0.221
|
|
<15 grade 1
|
5 (15.6)
|
27 (84.4)
| |
0 (0.0)
|
17 (100)
|
17
|
5 (33.3)
|
10 (66.7)
|
15
|
0.015
|
|
15-20 grade 2
|
9 (18.0)
|
41 (82.0)
|
1.000.a
|
3 (13.6)
|
19 (86.4)
|
22
|
6 (21.4)
|
22 (78.6)
|
28
|
0.713
|
|
>20 grade 3
|
50 (43.1)
|
66 (56.9)
|
0.002b
|
20 (44.4)
|
25 (55.6)
|
45
|
30 (42.3)
|
41 (55.7)
|
71
|
0.817
|
|
HV, mL
| | | | | | | | | |
0.203
|
| ≦60 |
29 (22.1)
|
102 (77.9)
|
<0.001
|
8 (13.1)
|
53 (86.9)
|
61
|
21 (30.0)
|
49 (70.0)
|
70
|
0.021
|
|
> 60
|
35 (52.5)
|
32 (47.8)
|
15 (65.2)
|
8 (34.8)
|
23
|
20 (45.5)
|
24 (54.5)
|
44
|
0.127
|
|
IVH
| | |
<0.001
| | | | | | |
0.221
|
|
0
|
12 (18.8)
|
52 (81.3)
| |
3 (10.0)
|
27 (90.0)
|
30
|
9 (26.5)
|
25 (73.5)
|
34
|
0.117
|
|
1-4 grade 1
|
10 (16.1)
|
52 (83.9)
|
0.816c
|
3 (11.1)
|
24 (88.9)
|
27
|
7 (20.0)
|
28 (80.0)
|
35
|
0.491
|
|
5-8 grade 2
|
19 (52.8)
|
17 (47.2)
|
<0.001a
|
6 (40.0)
|
9 (60.0)
|
15
|
13 (61.9)
|
8 (38.1)
|
21
|
0.201
|
|
9-12 grade 3
|
23 (63.9)
|
13 (36.1)
|
0.471b
|
11 (91.7)
|
1 (8.3)
|
12
|
12 (50.0)
|
12 (50.0)
|
24
|
0.025
|
|
Complications, n (%)
| | | | | | | | | |
|
RB
| | | | | | | | | |
0.221
|
|
No
|
57 (30.2)
|
132 (69.8)
|
0.006
|
22 (26.5)
|
61 (73.5)
|
83
|
35 (33.0)
|
71 (67.0)
|
106
|
0.334
|
|
Yes
|
7 (77.8)
|
2 (22.2)
|
1 (100)
|
0 (0.0)
|
1
|
6 (75.0)
|
2 (25.0)
|
8
|
1.000
|
|
RF
| | | | | | | | | |
0.221
|
|
NO
|
50 (28.2)
|
127 (71.8)
|
0.001
|
19 (24.1)
|
60 (75.9)
|
79
|
31 (31.6)
|
67 (68.4)
|
98
|
0.267
|
|
Yes
|
14 (66.7)
|
7 (33.3)
|
4 (80.0)
|
1 (20.0)
|
5
|
10 (62.5)
|
6 (37.5)
|
16
|
0.624
|
|
PI
| | | | | | | | | |
0.203
|
|
No
|
31 (26.7)
|
85 (73.3)
|
0.046
|
12 (24.0)
|
38 (76.0)
|
50
|
19 (28.8)
|
47 (71.2)
|
66
|
0.566
|
|
Yes
|
33 (40.2)
|
49 (59.8)
|
11 (32.4)
|
23 (67.6)
|
34
|
22 (45.8)
|
26 (54.2)
|
48
|
0.223
|
|
UGB
| | | | | | | | | |
0.221
|
|
No
|
56 (30.6)
|
127 (69.4)
|
0.087
|
19 (24.7)
|
58 (75.3)
|
77
|
37 (34.9)
|
69 (65.1)
|
106
|
0.139
|
|
Yes
|
8 (53.3)
|
7 (46.7)
|
4 (57.1)
|
3 (42.9)
|
7
|
4 (50.0)
|
4 (50.0)
|
8
|
1.000
|
- P values were calculated using the Wilcoxon or Kruskal-Wallis rank sum tests. Groups: A, minimal invasive puncture and drainage; B, decompressive craniectomy; GOS: Glasgow Outcome Scale; BP: blood pressure; SPB systolic blood pressure. DBP: diastolic blood pressure. GCS: Glasgow Coma Scale; NIHSS: National Institutes of Health Stroke Scale; HV: hematoma volume; IVH: intraventricular hemorrhage; RB: rebleed; PI: pulmonary infection; RF: renal failure; UGB: upper gastrointestinal bleeding; agrade 1 vs. grade 2; bgrade 2 vs. grade 3; cIVH 0 vs. IVH grade 1.
